

**Brilliant Violet 605® anti-mouse IL-4**

**Catalog # / Size:** 3120630 / 50 µg  
3120625 / 125 µl

**Clone:** 11B11

**Isotype:** Rat IgG1, κ


**Immunogen:** Partially purified native mouse IL-4

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** Lot-specific




PMA+ionomycin-stimulated (6 hours, in presence of brefeldin A) Th2-polarized C57BL/6 T cells were surface stained with CD4 FITC, and then intracellularly stained with IL-4 ( clone 11B11) Brilliant Violet 605™ (top) or rat IgG1, κ Brilliant Vio

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use

the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** **ELISA<sup>1,2,10,13</sup> or ELISPOT5 Capture:** The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.

**Neutralization<sup>1-2,9,12</sup>:** The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for neutralization of mouse IL-4 bioactivity *in vivo* and *in vitro* (Cat. No. 504108).

**Additional reported applications (for the relevant formats) include:** immunoprecipitation<sup>16</sup>, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections<sup>8</sup> and paraformaldehyde-fixed, saponin-treated frozen tissue sections<sup>6,7</sup>, and immunocytochemistry<sup>4</sup>.

**Note:** For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.

- Application References:**
1. Shirai A, *et al.* 1994. *Cytokine* 6:329. (ELISA, Neut)
  2. Abrams J. 1995. *Curr. Prot. Immunol.* John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
  3. Assenmacher M, *et al.* 1994. *Eur. J. Immunol.* 24:1097.
  4. Openshaw P, *et al.* 1995. *J. Exp. Med.* 182:1357. (ICC)
  5. Klinman D, *et al.* 1994. *Curr. Prot. Immunol.* John Wiley and Sons New York. Unit 6.19. (ELISA Capture)
  6. Litton M, *et al.* 1994. *J. Immunol. Methods* 175:47. (IHC)
  7. Andersson U, *et al.* 1999. *Detection and quantification of gene expression.* New York:Springer-Verlag. (IHC)
  8. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045. (IHC)
  9. Hara M, *et al.* 2001. *J. Immunol.* 166:3789. (Neut)
  10. Dzhagalov I, *et al.* 2007. *J. Immunol.* 178:2113. (ELISA)
  11. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366.
  12. Wang W, *et al.* 2007. *J. Immunol.* 178:4885. (Neut)
  13. Xu G, *et al.* 2007. *J. Immunol.* 179:5358. (ELISA) [PubMed](#)
  14. Ohnmacht C, *et al.* 2008. *Blood* 113:2816. [PubMed](#)
  15. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  16. Zavorotinskaya T, *et al.* 2003. *Mol. Ther.* 7:155. (IP)

---

**Description:** IL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation

of T helper subset development.

**Antigen  
References:**

1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Boulay J, *et al.* 1992. *Curr. Opin. Immunol.* 4:294.
3. Dullens H, *et al.* 1991. *In vivo* 5:567.
4. Paul